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Background: Burning mouth syndrome (BMS) is an enigmatic condition with the etiopathogenesis remaining 
largely obscure. However, a neuropathic basis for BMS continues to be an area of active clinical and research 
interest.
Aim: It is becoming increasingly evident that certain oral disorders may be modulated by imbalances in certain 
neuropeptides such as substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) there-
fore we measured SP, NKA and CGRP in the saliva and sera of BMS patients as well as controls.
Subjects and Methods: Salivary and serum SP, NKA and CGRP were determined in the 26 female patients with 
burning mouth syndrome (age range 51-78, mean 65.69 yrs), and in the 22 female controls (age range 24-82, mean 
49.72 yrs). Serum and salivary SP, NKA, CGRP levels were determined by commercial competitive enzyme im-
munoassay kits. Statistical analysis was performed by use of descriptive statistics and analysis of variance. 
Results and Conclusions: No significant differences in salivary SP, NKA and CGRP as well as serum SP and 
CGRP between BMS patients and controls could be found. However, significantly decreased serum neurokinin A 
(p<0.05) in BMS patients may reflect an inefficient dopaminergic system.
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Introduction
Burning Mouth Syndrome (BMS) is an oral sensory 
disorder diagnosed on the basis of history and the ab-
sence of any identifiable organic cause such as oral 
parafunctional habits, salivary gland dysfunction, local 
nerve trauma, menopausal disorders, diabetes, vitamin 
B group and iron deficiency (1). Notwithstanding the 
significant published literature on BMS, it continues to 
represent an enigmatic condition with the etiopathoge-
nesis remaining largely obscure. It is poorly diagnosed 
and in many cases poorly managed and as such repre-
sents a source of frustration for both clinicians and pa-
tients. A neuropathic basis for BMS continues to be an 
area of active clinical and research interest. It is still, 
however, a matter of conjecture whether BMS is a cen-
trally or peripherally induced pathologic condition. 
Svensson et al. (2) reported that BMS patients show an 
abnormal pre-pain perception intensity as well as dis-
turbances in non-nociceptive and nociceptive thermal 
stimuli perception. Gao et al. (3) reported alterations in 
neuronal transmission together with a hyperalgesia and 
probable allodynia of the trigeminal nerve. Heckmann 
et al. (4) found disturbances in the mucosal neurovas-
cular system. These reports together with taste changes 
and sensory/chemosensory disturbances (5-7) certainly 
support a neuropathic basis for BMS. 
It is becoming increasingly evident that periodontitis 
and indeed other orofacial inflammatory disorders may 
be modulated by imbalances in certain neuropeptides. 
In periodontitis affected subjects, levels of both SP and 
NKA were significantly elevated in gingival crevicular 
fluid of disease-affected teeth compared with healthy 
sites. The role of neuropeptides in exerting a trophic 
effect on peripheral tissues is also worthy of mention. 
Such system has been proposed to act tonically so that 
normal sensory stimuli would produce a continuous 
outflow of sensory transmitters whose actions would 
maintain tissue integrity (8).
It is also important to note that nociceptive signals from 
periphery may be amplified or diminished during spi-
nal processing, resulting in either central sensitization 
or desensitization, respectively. The stimulation of cap-
saicin-sensitive fibers (SP; CGRP) induce, on the one 
hand, an orthodromic noxious-sensory signal travel-
ling toward cortical areas, and on the other hand, an 
axoaxon reflex of primary sensory fibers which antidro-
mically releases transmitters from peripheral terminals 
evoking a number of changes in peripheral substrates 
(neurogenic inflammation, gland secretion, smooth 
muscle contraction). Therefore, it has been claimed that 
capsaicin-sensitive neurotransmitters are implicated in 
the pathophysiology of local reactions accompanying 
painful conditions. Despite the presence of degrading 
enzymes, saliva appears to be fluid which seemingly 
being close enough to peripheral receptors for sensory 
neuropeptides, can offer an image of the peptides re-
lease by sensory endings, roughly mirroring the central 
release pattern. In fact, capsaicin-sensitive neuropep-
tides (SP, CGRP) have unique property in that impulses 
may travel orthodromically or antidromically: therefore 
the transmitter may be released in both central and pe-
ripheral neural endings (9).
A number of neuropeptides exert a biologic effect that 
may play a role in the clinical presentation of BMS. 
Substance P (SP), neurokinin A (NKA) and calcitonin 
gene-related peptide (CGRP) for example all have active 
vasodilatory effects and the latter two play a direct role 
in pain. Furthermore they have attracted a considerable 
amount of attention in other pain syndromes including 
fibromyalgia and temporomandibular disorders (10). 
With the particular presentation scenario of BMS they 
may also be active in this condition. The aim of this 
project therefore was to evaluate salivary and serum 
SP, CGRP and NKA levels in the patients with BMS. 
The neuropeptides are released centrally and their le-
vels might be reflected in serum whereas their local re-
lease from peripheral sensory nerves might be reflected 
in saliva. These data might provide more specific data 
upon neuropathology in BMS as being either central or 
peripheral.
Materials and Methods
This project received clearance from the Institutional 
Ethics Committee and patients provided written in-
formed consent prior to commencement as required by 
Helsinki II. This study was realized during the years 
2006 and 2007. The study group consisted of 26 female 
patients, age range 51-78, mean 65.69 years, with BMS. 
The diagnosis was made on the basis of a detailed clini-
cal history and the exclusion of any local or systemic 
condition which may cause any type of oral dysaes-
thesia. They were not receiving specific treatment at 
the time of sampling. The control group consisted of 
22 females  with an age range of 24-82 and mean of 
49.72 years. This was marginally younger than the BMS 
group but a requirement for inclusion was that individu-
als were not taking any medications for the previous 
month and this alone skewed the group somewhat. 
All serum and saliva samples were collected between 
10.00 and 13.00 to avoid circadian variation. Partici-
pants provided unstimulated whole saliva over a five 
minute period without swallowing. One ml of saliva 
was added to clean plastic containers with 3.9 mg of 
ethylenediaminetetraacetate (EDTA) and 50 μl of apro-
tinin (70 mg v 50 ml of sodium hypochlorate which is 
500.000 KIE, Bayer AG, Germany) and the centrifuged 
at 1800 rpm for 10 minutes.
Serum was collected from the antecubital veins into 
vacuum tubes containing 3.9 mg of EDTA using stan-
dard venepuncture procedures (Venosafe evacuated 
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blood collection tubes, Terumo, N.V., Leuven, Belgium). 
One ml of serum was added to tubes containing 50 μl of 
aprotinin (70 mg v 50 ml of sodium hypochlorate which 
is 500.000 KIE, Bayer AG, Germany) and the mixture 
centrifuged at 1800 rpm for ten minutes. Serum speci-
mens were stored at -20 C. 
Serum and salivary neuropeptide levels were determined 
using commercial competitive enzyme immunoassay 
kits (Peninsula Laboratories Inc., Bachem Group, San 
Carlos, CA, USA) for human Substance P (Cat # S-1180, 
detection range 0-10 ng/ml), Neurokinin A (Cat # S-1280, 
detection range 0-25 ng/ml) and α-CGRP (Cat. # S-1199, 
detection range 0-25 ng/ml) with intra-assay and and 
inter-assay variabilities of < 5%  and < 14% respectively. 
Following the manufacturer’s instructions, 50 μl aliq-
uots of serum and saliva samples were dispensed into 
microplate wells and the target peptides were deter-
mined using a streptavidin-conjugated horseradish per-
oxidase with tetramethyl benzidine dihydrochloride as 
the substrate. The optical densities were read by the Dy-
natech MRX Microplate reader at 450 nm. The results 
were expressed in ng/ml of serum/saliva. 
The statistical analysis was undertaken using the sta-
tistical software package SPSS 10.0 for Windows. Des-
criptive statistics were used and the normality of dis-
tribution was tested by one-way Kolmogorov-Smirnov 
test. Because the test showed a normal data distribution, 
subsequent analysis with parametric tests were under-
taken. Analysis of variance (ANOVA) and pairwise 
comparisons (post hoc Scheffe test) were employed. 
P-values less than 0.05 were considered as significant 
(p<0.05).
Results
No significant difference in unstimulated whole sali-
vary flow rates was found between BMS patients and 
control subjects (p<0.05). 
Table 1 presents the descriptive statistics of the specific 
neuropeptides in serum and saliva in the control and 
BMS groups respectively. Table 2 shows the results 
of Mann-Whitney analyses with a significant differ-
ence representing a depression in the BMS group for 
serum NKA values (p<0.05). This depression does not 
however extend to any of the other neuropeptides in ei-
ther serum or saliva at statistically significant levels. A 
review of Table 1, however, does show that whilst the 
depressed NKA levels do not extend to saliva, there is 
a trend showing an elevation of both SP and CGRP in 
both serum and saliva, as well as neurokinin A in sa-
liva.
Discussion
The current study reviewed a limited number of BMS 
patients and, accepting the complexity of the condition 
described as BMS, the results are encouraging but at 
this early stage difficult to interpret with confidence.
Accepting that the aetiology of BMS is currently un-
known it seems likely that BMS conforms to the clinical 
pattern of a number of chronic pain conditions with the 
development of central nervous system pain processing 
abnormalities. This is the case for conditions as varied 
as fibromyalgia and temporomandibular joint disorders. 
In these conditions there seems to be a persistent noci-
ceptive input from the peripheral tissues to the central 
nervous system leading to neuroplastic changes and a 
resultant central sensitization and pain (10). The imme-
diate downstream outcome is that minimal peripheral 
stimulation only is required to maintain the chronic 
pain syndrome. Patients also experience involvement of 
previously uninvolved sites with the production of pain 
by very low grade stimulation. This is directly trans-
ferrable to the clinical presentation of BMS where the 
anterior dorsum and anterolateral tongue margins are 
most commonly involved with extension to other sites 
as a subsequent event or recognition only as a secon-
dary low grade phenomenon on clinical questioning. 
Decreased levels of dopamine likely contribute to the 
painful symptoms that frequently occur in Parkinson’s 
disease. Moreover, abnormalities in dopaminergic neu-
rotransmission have been objectively demonstrated in 
painful clinical conditions, including burning mouth 
syndrome, fibromyalgia and restless leg syndrome. Like-
wise, reduced levels of NKA in the serum of patients 
with BMS may reflect a deficiency in the dopaminer-
gic system and some commentators have suggested that 
such a deficient dopaminergic influence might actually 
be causative in BMS (11). Electrophysiological exami-
nations in BMS patients indicate an abnormal blink re-
flex which is under control of dopaminergic inhibitory 
control through the basal ganglia connection with the 
facial motor nuclei (12). An abnormal blink reflex is also 
a common finding in extra-pyramidal disorders such as 
Parkinson’s disease and facial dyskinesias (13,14) where 
it may be caused by a deficient dopaminergic influence 
on the brainstem nuclei. Further supportive evidence is 
found in a decreased dopaminergic inhibition in BMS 
patients which primarily affects trigeminal nerve noci-
ception and leads to the loss of sensory inhibition (15). 
A generalized and possibly multi-level abnormality in 
the processing of somatosensory information has also 
been found in BMS patients and this appears to be the 
result of peripheral neurogenic mechanism pathology 
(16). It is also well known that tachykinins such as SP 
and others are crucial for the functioning of dopami-
nergic neurons. 
Furthermore, decreased levels of NKA have been linked 
with number of drugs which act directly on receptors 
located on airway sensory nerves and inhibit neuropep-
tide release, for example opioids and local anesthetics 
(17). However, we couldnt find any association between 
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medications our BMS patients used and decreased se-
rum neurokinin A levels.
The salivary elevation of all investigated tachykinins 
although not being significant is interesting from two 
aspects. Salivary neuropeptides decrease in stimulated 
saliva (18) and so the current elevation does represent 
a real increase given the unstimulated saliva collection 
method. Secondly this increase might reflect neurogenic 
inflammation which might be causative to BMS. SP and 
NKA exert a wide variety of biological activities and 
are intimately linked with neurogenic inflammation, 
which has been shown to have a dose-dependent rela-
tionship with the levels of SP and/or NKA. One of the 
reasons why increased levels of salivary tachykinins did 
not reach significance might be mucosal atrophy which 
was found in 70% of BMS patients (19) which is known 
to influence the levels of certain salivary constituents 
i.e. (their leakage into saliva).
However, our results are not in concordance with the results 
of Zidverc-Trajkovic et al. (20) who reported that patients 
with BMS had decreased salivary CGRP levels. Further-
more, the same authors (20) conclude that this decrease is a 
consequence of trigeminal nerve degene-ration.
In conclusion the current investigation shows a strong 
trend to elevation of neuropeptides in both saliva and 
serum with the single exception of serum NKA. The 
implication is that this may play a direct role in the pro-
gression of BMS and explain comorbidities reported 
with this condition. Further investigation is required 
but the authors are encouraged by the present findings 
and feel that the likely relationship of BMS with other 
chronic pain syndromes may provide a direction for fu-
ture management.
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